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Elsewhere, we reported the safety and efﬁcacy results of a multicenter phase 3 trial of recombinant human a-
galactosidase A (rh-aGalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the
20-wk phase 3 double-blind, randomized, and placebo-controlled study received subsequently 1 mg/kg of rh-aGalA
(agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly in an ongoing open-label extension study. Evidence
of long-term efﬁcacy, even in patients who developed IgG antibodies against rh-aGalA, included the continuously
normal mean plasma globotriaosylceramide (GL-3) levels during 30 mo of the extension study and the sustained
capillary endothelial GL-3 clearance in 98% (39/40) of patients who had a skin biopsy taken after treatment for
30 mo (original placebo group) or 36 mo (original enzyme-treated group). The mean serum creatinine level and
estimated glomerular ﬁltration rate also remained stable after 30–36 mo of treatment. Infusion-associated reactions
decreased over time, as did anti-rh-aGalA IgG antibody titers. Among seroconverted patients, after 30–36 mo of
treatment, seven patients tolerized (no detectable IgG antibody), and 59% had 4-fold reductions in antibody
titers. As of 30 mo into the extension trial, three patients were withdrawn from the study because of positive serum
IgE or skin tests; however, all have been rechallenged successfully at the time of this report. Thus, enzyme replacement
therapy for 30–36 mo with agalsidase beta resulted in continuously decreased plasma GL-3 levels, sustained en-
dothelial GL-3 clearance, stable kidney function, and a favorable safety proﬁle.
Introduction
Fabry disease (MIM 301500) is an X-linked lysosomal
storage disease resulting from the deﬁcient activity of a-
galactosidase A and from the progressive accumulation
of globotriaosylceramide (GL-3) and related glycosphin-
golipids in the plasma and in tissue lysosomes through-
out the body (Desnick et al. 2001). In classically affected
males, vascular endothelial GL-3 accumulation in the
kidney, brain, and heart leads to early demise due to renal
failure, stroke, and cardiovascular disease (Colombi et al.
1967; Desnick et al. 2001; MacDermot et al. 2001).
A phase 1/2 clinical trial demonstrated that ﬁve bi-
weekly doses of 1.0 mg/kg of recombinant human a-
galactosidase A (rh-aGalA) (agalsidase beta, Fabra-
zyme, Genzyme Corporation) reduced the accumulated
GL-3 from the vascular endothelium of the kidney,
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heart, and skin of classically affected males (Eng et al.
2001a). Subsequently, a pivotal phase 3 double-blind,
randomized, placebo-controlled, and multicenter trial
evaluated the safety and efﬁcacy of rh-aGalA in 58 clas-
sically affected patients, including 2 females (Eng et al.
2001b). At the end of the 20-wk double-blind study,
69% (20/29) of the agalsidase beta–treated patients
showed GL-3 clearance to normal or near normal levels
in renal capillary endothelial cells, whereas none (0/29)
of the placebo-treated patients had cleared the glyco-
sphingolipid ( ). All 58 patients enrolled sub-P ! .001
sequently in an ongoing extension trial, and, after an
additional 6 mo of treatment, 100% (24/24) of the pa-
tients previously treated with placebo and 92% (23/25)
of the patients previously treated with agalsidase beta
had cleared GL-3 from their renal endothelial cells (Eng
et al. 2001b). Here, we report on the continued safety
and efﬁcacy of agalsidase beta replacement in patients,
after 30 mo of an ongoing open-label extension trial.
Subjects and Methods
Patients
All patients who completed successfully the phase 3
double-blind trial were eligible to enroll in the extension
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study and were required to provide written informed
consent prior to inclusion in the study (see Eng et al.
[2001b] for phase 3 inclusion/exclusion criteria and pa-
tient demographics). The open-label extension studywas
approved by the institutional review boards and/or
ethics committees of all participating centers.
Study Protocol
In the open-label extension study, all patients received
1 mg/kg (0.9–1.1 mg/kg) of agalsidase beta every 2 wk.
Prior to infusion, patients received 500–1,000 mg of
acetaminophen. Also, some patients were pretreated
with an antihistamine approved by the investigator. A
few patients received ibuprofen, prednisone, or both, as
pretreatment to minimize infusion-associated reactions
(IARs). Infusion rates were increased as tolerated, re-
sulting in a signiﬁcant reduction in infusion duration,
which, in some patients, decreased to 90 min. Patients
were eligible to transfer to local sites, after the ﬁrst 4
mo in the extension study. In addition, home infusions
were offered to patients who were clinically stable with
no IARs within the last 4 mo (eight infusions), who were
at the same infusion rate for a minimum of four infu-
sions, and who had no ongoing serious adverse events.
Serum IgE tests and, if needed, skin tests were per-
formed on patients who developed IARs suggestive of
an IgE-mediated response. If a preinfusion serum sample
was not available, a serum sample was drawn 3–8 d
after the reaction, for serum IgE testing. Skin testing
involved scariﬁcation (prick) tests and, if negative,
intradermal testing. Patients were withdrawn from the
study by protocol if their serum IgE or skin test was
positive and were eligible for a cautious rechallenge with
agalsidase beta, with the use of the following infusion
scheme: the ﬁrst two infusions of agalsidase beta were
administered at a dose of 0.5 mg/wk at a starting rate
not exceeding 0.01 mg/min, which then could be dou-
bled every 30 min for the remainder of the infusion (to
a maximum rate of 0.25 mg/kg/min) if no signiﬁcant or
intolerable infusion-associated symptoms occurred. Sub-
sequently, the dose could be increased to 1.0 mg/kg of
agalsidase beta intravenously every other week for the
duration of the study. Pretreatment was not permitted
for the ﬁrst four infusions in this protocol, to allow early
recognition of acute systemic reactions. Antihistamines,
antipyretics, b-agonists, or steroids were permitted for
subsequent infusions, in consultation with Genzyme
Pharmacovigilance. In addition, patients on beta block-
ers were asked to stop this medication 2 d prior to the
infusion until 12 h after the infusion.
Results reported here document the ﬁrst 30 mo of
agalsidase beta treatment in the extension study. Patients
who received agalsidase beta in the double-blind study
have received 36 mo of treatment and are designated as
the “agalsidase beta/agalsidase beta” group. Patients
who received placebo in the double-blind study have
received 30 mo of treatment and are designated as the
“placebo/agalsidase beta” group.
Assessment of Skin Biopsies
Skin biopsies were obtained by punch biopsy (3 mm)
at the baseline of the placebo-controlled trial; at com-
pletion of the placebo-controlled trial (20 wk); at 6 mo,
12 mo, and 18 mo into the extension trial; and annually
thereafter. Tissue sections (1 mm) were stained with
methylene blue-azure II, as described elsewhere (Eng et
al. 2001b). Specimens were observed via light micros-
copy for accumulation of GL-3. Specimens with no mi-
crovascular endothelial deposits of GL-3 or only trace
amounts (normal or nearly normal) were given a score
of 0. Specimens in which the majority of vessels had
evidence of a single endothelial inclusion were given a
score of 1. Specimens that contained multiple vessels
with multiple sites of single or multiple inclusions were
given a score of 2. Specimens that had large accumu-
lations of inclusions, with some clusters at the juxta-
nuclear region and around cytoplasmic borders, and
bulging of the vessel lumens were given a score of 3.
Clinical and Biochemical Assessments
The following assessments were performed every 6mo
during the extension study: (1) vital signs, physical ex-
amination, routine blood chemistries, hematology, and
urinalysis; (2) serum creatinine and the mean estimated
glomerular ﬁltration rate (GFR), calculated by the Mod-
iﬁcation of Diet in Renal Disease Study (MDRD) equa-
tion (Levey et al. 2000) on the basis of patients’ age,
race, sex, and serum-creatinine values; (3) proteinuria
(determined with the use of the urine protein:urine cre-
atinine ratio, which represents the approximate urine
protein excretion in g/d); (4) 12-lead EKG; (5) health
status, evaluated with the Short Form-36 (SF-36) Health
Status Survey (Ware et al. 1997); and (6) pain score,
evaluated with the short formMcGill pain questionnaire
(Melzack 1987). Echocardiography was performed
annually.
Plasma GL-3 concentrations were determined initially
in the phase 3 trial with the use of an ELISA method
(Zeidner et al. 1999) at the following times: baseline,
14 wk, and 20 wk of the phase 3 double-blind study
and entry, 6 mo, and 12 mo of the open-label extension
study (Eng et al. 2001b). Samples obtained at 18 mo,
24 mo, and 30 mo into the extension study, along with
archived baseline samples of the double-blind study,
were analyzed with the use of a more sensitive mass-
spectrometric assay (Genzyme Data on File). In brief,
total lipids were extracted from plasma via chloroform/
methanol liquid-liquid extraction. Neutral glycosphin-
golipids were isolated from the organic phase layer and
further puriﬁed by C18 chromatography. The puriﬁed
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extract was dried and reconstituted in methanol, and the
total GL-3 was quantiﬁed by analyzing the sample with
a multiple reactions monitoringmode LC/MS/MS (liquid
chromatography/tandem mass spectroscopy) . The con-
stant neutral loss of the galactosyl group (m/z 162) from
GL-3 during MS/MS analysis has permitted both con-
ﬁrmation of identity and development of a sensitive
quantiﬁcation scheme. Total GL-3 is quantiﬁed by the
sum of the 10 major isoforms (C16:0-, C18:0-, C20:0-,
C22:0-, C22:1-, C22:0-OH, C24:0-, C24:1-, C24:0-OH,
and C26:0-GL-3) measured in the plasma sample with
the use of C17:0, a nonnaturally occuring isoform of
GL-3, as an internal standard. The upper limit of normal
for plasma GL-3, with the use of the more sensitivemass-
spectrometric assay, was 7.03 mg/ml, on the basis of the
estimated 99th percentile value from 205 normal plasma
samples from a blood bank (the mean SD of the 205
samples was 3.5  1.3 mg/ml).
Antibodies
Blood was drawn prior to every other infusion, and
the serum was screened for the presence of IgG anti-
bodies against rh-aGalA with the use of an ELISA spe-
ciﬁc for rh-aGalA. The results were conﬁrmed by a ra-
dioimmunoprecipitation (RIP) assay. Quantitation of the
antibody was done by titrating the antibody reactivity
with the ELISA assay, following a 2-fold dilution scheme
starting at 1/100. Normal distribution studies of 1100
normal human sera have shown that this initial dilution
(1/100) had minimal reactivity in the ELISA and was
essentially “background” for normal serum. If a patient
did not seroconvert throughout the entire study period,
then the patient was deﬁned as having no immune re-
sponse (“seronegative”). If a patient seroconverted and
later ceased producing IgG antibodies, as determined by
the ELISA assay within the normal range and by two
consecutive negative conﬁrmatory RIP assays, then the
patient was deﬁned as having “tolerized.” The remaining
patients who seroconverted without tolerizing were clas-
siﬁed as follows. “Low responders” were deﬁned as
those who did not tolerize and whose highest titer value
was 800 (i.e., 1:8 above background). Patients who
did not tolerize and had at least one titer value 1800
and a 4-fold decrease in titer from the peak to the last
value were designated as having a “downward trend.”
Patients for whom at least one titer was 1800 and the
highest titer to date was achieved at the last visit were
given the titer classiﬁcation of “highest titer to date.”
Patients who seroconverted but did not ﬁt any of the
above criteria were deﬁned as having “plateaued.”
Statistical Analysis
For skin biopsies, the exact binomial matched pairs
procedure was used to determine if there was a statis-
tically signiﬁcant difference in the proportion of patients
showing a change from entry to 30 mo of treatment in
the extension study. Two-tailed tests were used for all
analyses. One-sample t-tests were used to compare the
mean changes in glomerular ﬁltration, pain, and SF-36
scores within groups, from entry to 30 mo into the
extension study. was considered statisticallyP  .05
signiﬁcant.
Results
Patient Characteristics
All 58 patients who participated in the phase 3 double-
blind, randomized, and placebo-controlled trial enrolled
in the open-label extension study. Their baseline char-
acteristics were described elsewhere (Eng et al. 2001b).
By month 30 of the open-label extension trial, eight pa-
tients had withdrawn (because of voluntary withdrawal
[four patients], protocol-speciﬁed criteria [three], or
death [one]). Three patients, who were withdrawn by
protocol, had a positive serum IgE or skin test. At the
time of this report, all three patients were rechallenged
with agalsidase beta, either with the commercial drug
or in a rechallenge protocol, and continue to be treated
(the EMEA approved Fabrazyme in June 2001, and the
FDA approved Fabrazyme in April 2003). No patient
experienced anaphylaxis. One 43-year-old patient died
10 d after infusion 29; he collapsed at home, and re-
suscitation was unsuccessful. He had a history of a my-
ocardial infarction at age 30 years and a pacemaker for
severe bradycardia at age 43 years, and he had left-
ventricular hypertrophy and heart failure. An autopsy
revealed acute heart failure and severe cardiovascular
involvement consistent with Fabry disease.
Efﬁcacy of Long-Term Therapy
As shown in ﬁgure 1, the mean values for plasma GL-
3 were in the normal range at 18 mo and have remained
normal after 30–36 mo of treatment for the original
placebo and the agalsidase beta–treated groups in the
double-blind study, respectively. The mean plasma GL-
3 concentrations, determined by the mass spectrometric
assay, were 4.9 mg/ml and 5.0 mg/ml for the placebo/
agalsidase beta and agalsidase beta/agalsidase beta
groups after 30–36 mo of treatment, respectively. The
mean plasma GL-3 levels were reduced into the normal
range in 94% (44/47) of the patients who had plasma
data available after 30–36 mo of treatment (ﬁg. 1). The
three outliers had values of 9.1, 8.2, and 8.0 mg at 30
mo, compared with baseline values of 15.6, 16.6, and
14.0 mg, respectively. None of the patients with the el-
evated plasma GL-3 levels at month 30 had a missed
infusion prior to the plasma GL-3 sampling. Two of the
three patients with elevated plasma GL-3 levels at month
30 had normalized their plasma GL-3 levels at a sub-
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Figure 1 Mean (SD) plasma GL-3 concentration (mg/ml),mea-
sured by mass spectrometry at baseline and at 18 mo, 24 mo, and 30
mo into the phase 3 extension study, showing normalization of mean
plasma GL-3 levels after agalsidase beta therapy. At 30 mo into the
extension study, 94% of patients had normal plasma GL-3 values. The
mean (SD) values of the control group were 3.5 (1.3) mg/ml. The
number of patients is indicated in parentheses below the graphed
points.
sequent time; the third patient did not have a plasma
GL-3 level available at the time of this report.
Skin biopsies were obtained from 40 patients after 30
mo of the extension study. Of these, 98% (39/40) had
capillary endothelial cell scores of 0, consistent with con-
tinuous GL-3 clearance (ﬁg. 2). The single patient with
a nonzero score at 30 mo of treatment had a score of
1 (his baseline score was 2), whereas his serum creatinine
was 1.0 mg/dl, his estimated GFR was 94.9 ml/min/1.73
m2, his plasma GL-3 level was 5.8 mg/ml, and his anti-
body titers decreased over time (i.e., a downward trend).
Renal function, assessed by mean serum creatinine
and estimated GFR, remained stable throughout the 30-
mo extension study for both study groups (ﬁg. 3A). At
entry to the extension trial, the mean serum creatinine
concentrations for both the placebo/agalsidase beta and
agalsidase beta/agalsidase beta groups were normal
(0.8 and 0.9 mg/dl, respectively) and remained normal
through 30 mo of the extension study (mean serum cre-
atinine of 0.9 and 1.0 mg/dl, respectively). Of note, after
30 mo of treatment with Fabrazyme in the phase 3 open-
label extension study, three patients had a 150% increase
in their serum creatinine levels, with the last value being
11.4 mg/dl from the start of treatment. The increase in
SD over time is reﬂective of the three patients who had
a 150% increase in their serum creatinine value from
the start of treatment. These are the only three patients
in the study who, at baseline, had both prominent glom-
erulosclerosis and a urinary protein:urinary creatinine
ratio 12.0 (representing an approximate urine protein
excretion of 12 g/d). In addition, all three patients were
age 140 years, the age range at which most patients with
Fabry disease demonstrate a decline in renal function
(Colombi et al. 1967; Branton et al. 2002; Thadhani et
al. 2002). When these three patients were removed from
the serum creatinine calculation, the mean values for the
placebo/agalsidase beta and agalsidase beta/agalsidase
beta groups were 0.8 and 0.9 mg/dl, respectively (ﬁg.
3B).
An assessment of the number of glomeruli showing
focal segmental glomerulosclerosis, the number showing
global glomerulosclerosis, and the number that appeared
normal had been performed on the 48 patients who had
renal biopsies at all three earlier-speciﬁed times (baseline
of the double-blind study, end of the double-blind study,
and 6 mo into the open-label extension study). Of these
48 patients, 43 had glomeruli present in both the base-
line and 6-mo extension biopsies. Review of these anal-
yses demonstrated that, for 14% (6/43) of patients,
150% of all observed glomeruli demonstrated either fo-
cal segmental glomerulosclerosis or global glomerulo-
sclerosis in the baseline kidney biopsy (table 1). The
three patients, discussed above, who had deterioration
of renal function are in this group of six patients.
At entry into the extension trial, the mean estimated
GFRs for both the placebo/agalsidase beta and agalsi-
dase beta/agalsidase beta groups (138.3 and 109.6 ml/
min/1.73 m2, respectively) were normal and remained
normal through 30 mo of the extension study (mean
estimated GFRs of 129.5 and 107.1 ml/min/1.73 m2,
respectively). Of note, a subset of 10 patients in this trial
had low estimated GFR values (!90 ml/min/1.73 m2)
prior to the start of treatment with agalsidase beta. For
these 10 patients, the mean (SD) GFR values prior to
treatment and 30–36 mo later were 68.6 (19.65) and
79.6 (6.27) ml/min/1.73 m2, respectively. After 30–36
mo of agalsidase beta treatment, 7 (70%) of the 10 pa-
tients had either stabilized their estimated GFR values
(GFR  20%) or improved.
The median urinary protein-to-creatinine ratio, for
both treatment groups combined, was 0.221 at baseline
of the double-blind study and remained stable at 0.198
after 30–36 mo of rh-a-GalA therapy ( ; all pa-Np 27
tients who had data available at both times), indicating
a stabilization in urine protein excretion. As shown in
ﬁgure 4, the few patients who had an increase in urine
protein excretion had relatively high proteinuria at base-
line, suggesting that baseline factors may play a role in
response to therapy.
A slight improvement was observed during the open-
label extension study in both treatment groups for most
SF-36 parameters; however, these changes were not
statistically signiﬁcant. Pain scores, as assessed by the
McGill pain questionnaire, remained low throughout the
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Figure 2 GL-3 clearance in dermal superﬁcial endothelial cells in phase 3 double-blind trial and extension study (% zero scores). Clearance
of GL-3 from the dermal capillaries was sustained after prolonged agalsidase beta therapy. PL p placebo; AB p agalsidase beta.
extension study. It should be noted that patients had low
pain scores at entry (the mean total pain scores were 2.0
for the placebo/agalsidase beta group and 4.1 for the
agalsidase beta/agalsidase beta group; the highest pos-
sible pain score is 45).
Starting at month 24 of the extension study, the in-
vestigators asked their patients to report pain-medica-
tion usage in the preceding 3 mo. Four patients in the
agalsidase beta/agalsidase beta group and one patient in
the placebo/agalsidase beta group stopped all pain med-
ications between months 27 and 30. Four patients in the
agalsidase beta/agalsidase beta group and two patients
in the placebo/agalsidase beta group had reduced the
dose and/or the frequency of their pain medications.
However, most patients taking pain medications (np
) used them on an as-needed basis.34
Safety of Long-Term Therapy
The most common related adverse events occurred
during the infusions and consisted of rigors, tempera-
ture-change sensation (feeling cold or warm), fever,
nausea, headache, and nasal congestion. These adverse
events were generally mild and tolerable, and patients
were managed with infusion rate reduction and, if
needed, with additional medications. Initially, IARs oc-
curred usually between infusions 5 and 7 (coinciding
with seroconversion). Only one of the seven seronegative
patients experienced an IAR. As shown in ﬁgure 5, the
percentage of patients experiencing IARs decreased over
time. Eight patients experienced serious adverse events,
which were most often infusion-associated events, in-
cluding tachycardia, hypertension, urticaria, chest pain
and/or throat tightness, fevers, and rigors.
It should be noted that the current phase 3 extension
study was not designed to assess the effect of enzyme
replacement therapy (ERT) on clinical outcomes. Data
on stroke and cardiovascular events were not collected
as part of the study but rather as adverse events. Hence,
detailed information was not available. Nonetheless,
8.6% (5/58) of patients were reported to have cerebro-
vascular events (stroke or transient ischemic attack) at
the time of this report. One of these ﬁve patients had
an extensive past history of stroke. The other four pa-
tients, presumably, did not have a prior history of stroke.
These patients did not have renal failure or cardiac com-
plications during the study. The lack of a placebo group
makes interpretation of these data difﬁcult. Review of a
large historical database of patients with Fabry aged
16 years shows that 13.7% (57/415) of patients had
a cerebrovascular event (Genzyme Data on File).
The rate of seroconversion among enzyme-treated
patients was 89.7% (52/58), and, among those who
seroconverted, the median time to seroconversion was
∼6 wk, with a median time of 63 d to peak titer. After
30 mo of the extension study, 10.3% (6/58) of patients
remained seronegative. There were no obvious charac-
teristics that might help to identify prospectively patients
who will not seroconvert. Of the 52 patients who sero-
converted, 1 patient was excluded from the longitudinal
analysis because he withdrew from the phase 3 open-
label study after infusion 8, and comparative antibody
titers were available only for a short duration of time.
Of the remaining 51 patients, 13.7% (7/51) tolerized,
3.9% (2/51) were low responders, 19.9% (10/51) pla-
teaued, 3.9% (2/51) had their highest titers at their last
visit, and 58.8% (30/51) had downward trends in their
antibody titers. For the two patients whose highest titers
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Figure 3 Mean (SD) serum creatinine concentrations (mg/dl) at baseline during the phase 3 extension. A, Mean serum creatinine
concentration, normal at baseline and during the phase 3 double-blind trial and phase 3 extension study. The increase in SD over time reﬂects
the three patients who had 150% increase in serum creatinine from the start of treatment with agalsidase beta. B, Mean (SD) serum creatinine
concentration after the three patients with advance disease were removed from the analysis. The number of patients is indicated in parentheses
below the graphed points.
were at the last visit, there has been no decline in efﬁcacy
of treatment for either subject, as evidenced by their skin
biopsy histologic scores of 0 and their normal plasma
GL-3 (6.2 and 6.2 mg/ml, respectively) and serum cre-
atinine (0.8 and 1.2 mg/dl, respectively) levels at month
30. Of note, one of the two females in the study was a
low responder (peak titerp 400) and tolerized, whereas
the other remained seronegative throughout the study.
After the double-blind study, progressive increases in
the rate of administration were allowed at all sites. At
month 30 of the extension study, 93% (54/58) of pa-
tients completed one or more infusions in 2.5 h, with
a mean infusion time of 2.2 h, and 78% (45/58) of
patients completed one or more infusions in 2.0 h.
Discussion
In Fabry disease, affected males with the classic pheno-
type uniformly develop renal disease, typically by 35–
45 years of age, with an average of ∼42 years (Colombi
et al. 1967; Desnick et al. 2001; Branton et al. 2002;
Thadhani et al. 2002). Since early renal failure primarily
results from GL-3 accumulation in endothelial and
glomerular cells, therapeutic endeavors have focused on
stabilizing or reversing the renal pathology (Schiffmann
et al. 2000; Eng et al. 2001a). A phase 3 double-blind,
randomized, and placebo-controlled trial and an open-
label extension study described the safety and effective-
ness of rh-aGalA replacement therapy using agalsidase
beta (Fabrazyme, Genzyme Corporation) at 1 mg/kg bi-
weekly (Eng et al. 2001b). The primary endpoint—the
clearance of accumulated GL-3 to normal or near nor-
mal levels from renal microvascular endothelial cells—
was documented in 96% (47/49) of patients after 6–12
mo of agalsidase beta treatment (Eng et al. 2001b; Thur-
berg et al. 2002). In addition, accumulated GL-3 de-
posits were reduced to normal or near normal levels in
renal mesangial cells, glomerular capillary endothelium,
noncapillary endothelium, and interstitial cells. GL-3 de-
posits were reduced also in vascular smoothmuscle cells,
tubular epithelium, and podocytes, although at a slower
rate (Thurberg et al. 2002). In addition, the plasma GL-
3 levels normalized and the mean serum creatinine and
estimated GFR remained stable after 6–12 mo of agal-
sidase beta treatment (Eng et al. 2001b; Thurberg et al.
2002). Here, we report the 30-mo results of the phase
3 open-label extension study, which demonstrate the
continued safety and efﬁcacy of agalsidase beta replace-
ment therapy at 1 mg/kg biweekly.
A major question addressed by the extension study
was whether long-term ERT could sustain the dramatic
GL-3 clearance described in the double-blind study and
in the ﬁrst 6 mo of the extension study (Eng et al. 2001b)
and, in particular, whether the IgG antibodies against
the recombinant enzyme would impair efﬁcacy. In ad-
dition, since renal failure is the most uniform and dev-
astating feature in classic Fabry disease, the long-term
effects on kidney function in these patients, some of
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Table 1
Clinical Characteristics of Patients with Sclerosis of 50% Glomeruli at Baseline
Patient Treatment Group
Baseline
Age
(years)
Ratio of Baseline
Urine Protein to
Urine Creatininea
Serum
Creatinineb,c
(mg/dl)
30-Mo Serum
Creatinine
(mg/dl)
% Increase
in Serum
Creatininec,d
110 Placebo/agalsidase beta 26 NA 1.0 1.4 40
119 Placebo/agalsidase beta 48 3.56 1.6 3.1 93.8
707 Agalsidase beta/agalsidase beta 45 2.92 .7 1.8e 157.1
708 Placebo/agalsidase beta 41 1.48 .8 .7 12.5
709 Placebo/agalsidase beta 30 .79 1.1 1.2 9.1
804 Agalsidase beta/agalsidase beta 42 2.03 1.1 3.2 190.9
a NA p not available.
b Prior to the start of treatment with agalsidase beta.
c The start of treatment for the agalsidase beta/agalsidase beta patients is the baseline of the phase 3 placebo-controlled study,
and the start of treatment for the placebo/agalsidase beta patients is the entry of the phase 3 extension study.
d From the start of treatment with agalsidase beta to 30 mo into the extension study.
e 24-mo value (30-mo value not available).
whom initially had histologic evidence of severe renal
damage and signiﬁcant proteinuria, were evaluated.
Biochemical evidence for the persistent effectiveness
of agalsidase beta therapy at 1 mg/kg biweekly was the
continuous normalization of the mean plasma GL-3 lev-
els in the patient groups who had 30–36 mo of treat-
ment (ﬁg. 1). In the phase 3 double-blind study and in
the ﬁrst 6 mo of the extension study, the mean plasma
levels were reduced to nondetectable levels with the use
of an ELISA method to quantitate plasma GL-3. A new,
more sensitive and robust mass-spectrometric method
was employed to reassay the original baseline specimens
and those obtained during the course of the extension
study. The mean plasma GL-3 levels were reduced con-
tinuously into the normal range in 94% (44/47) of the
patients who had plasma data available after 30–36 mo
of treatment (ﬁg. 1). In addition, histologic evidence for
persistent GL-3 clearance from vascular endothelial cells
was provided by examination of serial skin biopsies. In
98% of the 40 patients who had skin biopsies after 30–
36 mo of treatment, GL-3 clearance was achieved and
maintained (ﬁg. 2). Only one patient had a score of 1,
and his baseline score was 2.
The average age of the patients at baseline of the
phase 3 double-blind study was 30.2 years, and, as ex-
pected, their mean serum creatinine was normal: 0.8
0.2 mg/dl. After 30–36 mo of treatment, the mean se-
rum creatinine levels were 0.9 and 1.0 mg/dl for the
placebo/agalsidase beta and agalsidase beta/agalsidase
beta groups, respectively (ﬁg. 3A). Nonetheless, three
patients, all aged 140 years and with signiﬁcant baseline
pathology, as assessed by the presence of glomerular
sclerosis and nephrotic-range proteinuria, had progres-
sion of renal insufﬁciency. Indeed, when these three pa-
tients with advance diseased were excluded from the
serum creatinine analysis, the mean and SD decreased
(ﬁg. 3B), indicating continued stable renal function in
the remaining patients. These data suggest that treat-
ment before extensive renal damage occurs is critical
and that there may be a “point of no return,” in which
impaired glomeruli will progress irreversibly to failure.
Clearly, prevention of renal disease requires early ther-
apeutic intervention in all classically affected males and
substantially affected carriers (Desnick et al. 2003). To
wait for elevated serum creatinine levels, when more
than half the renal function has been lost, before ini-
tiating treatment may be counterproductive.
On the basis of our data, we cannot determine the
effect of treatment on cerebrovascular risk. Given that
there is likely to be at least some irreversible pathologic
damage in patients ﬁrst treated in adulthood, such pa-
tients are probably at increased cardiac and cerebro-
vascular risk. Therefore, every effort should be made to
aggressively control other risk factors, such as hyper-
lipidemia, hypertension, and smoking. Prophylactic
aspirin is prescribed commonly for men 135 years old
with Fabry; however, the effectiveness of this therapy
in this population is currently unknown.
Improvement in pain is notoriously difﬁcult to assess.
Indeed, in the double-blind placebo-controlled trial, sta-
tistically signiﬁcant improvement in pain scores was ob-
served in both placebo- and agalsidase-treated groups.
Nonetheless, during the phase 3 extension trial, some
patients reported a decrease in or cessation of the use
of pain medications, suggesting that longer treatment
decreased the frequency and/or intensity of their pain
and/or the need for pain-relieving medications. In fact,
most patients required pain medications only on an
as-needed basis.
Generally, infusions of agalsidase beta were well-
tolerated by patients, with the frequency of IARs de-
clining over the course of the study. There were no re-
ports of anaphylaxis, and the three patients who were
withdrawn by protocol, because of a positive serum IgE
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Figure 4 Urinary protein excretion. Urine protein:urine creatinine, the ratio representing the approximate urine protein excretion in
g/d, remained stable from the baseline of the double-blind study to 30 mo into the extension study. Change in urine protein excretion is associated
with baseline proteinuria. This ﬁgure presents data on all 27 patients for whom data were available at both times.
or skin test, have been rechallenged subsequently with
success. Thus, the clinical signiﬁcance of these tests re-
mains unclear.
IgG antibodies were found in ∼90% of treated pa-
tients, and the median time to serocoversion was ∼6
wk. This was expected, since most classically affected
males with Fabry disease are negative for cross-reacting
immunologic material (CRIM), as a result of frameshift,
missplicing, stop codon, or unstable missense muta-
tions. However, 13.5% of the seroconverted patients
tolerized (no detectable IgG antibodies), and the ma-
jority of seroconverted patients demonstrated a4-fold
reduction in antibody titer over the 30-mo extension
study. Notably, seroconversion did not affect long-term
efﬁcacy of agalsidase beta treatment, as evidenced by
persistently normalized plasma GL-3 levels, sustained
GL-3 clearance in skin capillaries, and stable renal func-
tion. In comparison, ∼15% of patients with type 1
Gaucher disease, who have residual acid b-glucosidase
activity and are CRIM-positive, raise nonneutralizing
IgG antibodies during ERT (Richards et al. 1993; Ro-
senberg et al. 1999). However, experience with ERT in
type 1 Gaucher disease for 110 years has demonstrated
that seroconverted patients developed tolerance and
that therapeutic efﬁcacy was not impaired by the pres-
ence of IgG antibodies (Rosenberg et al. 1999).
Moreover, recent clinical experiences and non–
placebo-controlled studies have indicated that ERTwith
agalsidase beta stabilized renal function (De Schoen-
makere et al. 2003), improved cardiac function (Waldek
2003; Weidemann et al. 2003), and improved quality
of life (Guffon and Fouilhoux, in press). Several inves-
tigators participating in this study have also noted,
among some patients, improvement in speciﬁc clinical
manifestations, including fatigue, exercise tolerance,
abdominal pain, diarrhea, ability to sweat, and lymph-
edema. In addition, most patients report decreased and/
or less-frequent Fabry pain, but these ﬁndings have
varied among patients.
Clearly, additional experience is required to demon-
strate the long-term effectiveness of agalsidase beta ther-
apy on renal, cardiac, and cerebrovascular manifesta-
tions, which are the major causes of premature death
in this disease. However, it has been recommended by
physicians who are expert in Fabry disease that all af-
fected males and carriers with substantial manifesta-
tions should be treated, with treatment being initiated
as early as possible to prevent disease manifestations
(Desnick et al. 2003). A Fabry disease registry has been
established to follow patients long term and to assess
the effect of ERT on this disease (Fabry Registry).
In summary, this open-label extension study of agal-
sidase beta replacement extends the ﬁndings of the dou-
ble-blind, randomized, and placebo-controlled trial and
demonstrates that, after 30–36 mo of treatment, ERT
continued to be safe and effective. The continuous efﬁ-
cacy was evaluated on the basis of the relatively nonin-
vasive serial determinations of substrate accumulation,
including persistently normalized plasmaGL-3 levels and
the continuous clearance of GL-3 deposits from the vas-
cular endothelium of biopsied skin. The absence of reac-
cumulated GL-3 in plasma and vascular endothelial cells
indicates that the replaced enzyme, even in the presence
of IgG antibodies, continuously cleared the plasma and
the vascular endothelial cells that are the major target
sites of pathology in Fabry disease (Desnick et al. 2001).
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Figure 5 Percentage of patients experiencing IARs during the phase 3 double-blind and phase 3 extension studies, decreasing over time.
The number of patients is indicated in parentheses below the graphed points.
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